HIV Infection
Conditions
Keywords
HIV infection, raltegravir use, women
Brief summary
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.
Interventions
DRUGraltegravir
HIV therapy component
Sponsors
The University of Texas Health Science Center, Houston
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center. 2. Minority women -Black/African American, Hispanic/Latino
Exclusion criteria
* n/a
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load | 24 weeks of therapy |
Secondary
| Measure | Time frame |
|---|---|
| Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus) | 24 weeks of therapy |
| Assess tolerability of raltegravir by capturing symptoms | 24 weeks of therapy |
Countries
United States
Outcome results
None listed